<DOC>
	<DOCNO>NCT01844427</DOCNO>
	<brief_summary>This 12-week clinical trial evaluate efficacy safety memantine hydrochloride ( Memantine HC1 , brand name Namenda ) treatment executive function deficit ( EFDs ) adult Attention Deficit Hyperactivity Disorder ( ADHD ) . After screen procedure , memantine prescribe randomize , double-blind fashion ( equal chance medication placebo ) 12 week . The investigator hypothesize memantine hydrochloride prove effective , safe , well-tolerated agent treatment EFDs individual ADHD interest non-stimulant medication .</brief_summary>
	<brief_title>Memantine Monotherapy Executive Dysfunction ADHD</brief_title>
	<detailed_description />
	<mesh_term>Memantine</mesh_term>
	<criteria>1 . Male female adult age 1845 year ; 2. diagnosis DSMIV [ 78 ] ADHDcombined type 3. score least 20 AISRS ( score 20 AISRS identifies subject least moderate severity symptom ) ; 4. BRIEFA Global Executive Composite Tscore &gt; 6 ; 5. proficiency English . 1 ) Pregnant nursing female ; 2 ) investigator his/her immediate family ( spouse , parent , child , grandparent , grandchild ) ; 3 ) serious , unstable medical illness include hepatic , renal , gastroenterological , respiratory , cardiovascular ( include ischemic heart disease hypertension ) , endocrinologic , neurologic , immunologic , hematologic disease ; 4 ) hypersensitivity memantine ; 5 ) multiple adverse drug reaction ; 6 ) current past history seizure ; 7 ) history major psychiatric disorder include schizophrenia , psychosis , bipolar disorder ( BPD ) , autism spectrum disorder ( ASD ) ; 8 ) meet DSMIV criterion last month major depression major anxiety disorder Hamilton Rating Scale Anxiety ( HAMA ) Hamilton Rating Scale Depression ( HAMD ) score great 14 ; 9 ) meet DSMIV criterion substance abuse dependence last month positive drug urine screen ; 10 ) judge serious suicidal risk ; 11 ) use concomitant medication primarily central nervous system activity ; 12 ) IQ &lt; 80 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Executive function deficit</keyword>
	<keyword>Psychiatry</keyword>
	<keyword>Psychopharmacology</keyword>
	<keyword>Namenda</keyword>
</DOC>